Related Experiment Video
Updated: Jul 14, 2026

Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding
Published on: September 15, 2010
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with
Rebecca A Russell1, Vinay K Pathak
1HIV Drug Resistance Program, National Cancer Institute-Frederick, P.O. Box B, Bldg. 535, Rm. 334, Frederick, MD 21702-1201, USA.
Insights
Human immunodeficiency virus type 1 (HIV-1) Vif protein has two key regions, Y(40)RHHY(44) and D(14)RMR(17), that bind to host restriction factors APOBEC3G and APOBEC3F. Targeting these Vif-APOBEC3 interactions offers a potential antiviral strategy.
Area of Science:
- Virology
- Molecular Biology
- Immunology
Background:
- Human cytidine deaminases APOBEC3G (A3G) and APOBEC3F (A3F) are host restriction factors that inhibit human immunodeficiency virus type 1 (HIV-1) replication.
- The HIV-1 Vif protein antagonizes A3G and A3F by mediating their proteasomal degradation, thus enabling viral replication.
Purpose of the Study:
- To identify the specific regions of HIV-1 Vif responsible for binding to and antagonizing A3G and A3F.
- To explore the potential of targeting Vif-APOBEC3 interactions for antiviral drug development.
Main Methods:
- Extensive mutational analysis of HIV-1 Vif protein.
- Assessment of Vif binding to A3G and A3F.
- Evaluation of Vif's ability to suppress A3F and neutralize Vif-resistant A3G mutants.
Main Results:
- Two distinct Vif determinants were identified: Y(40)RHHY(44) for A3G binding and D(14)RMR(17) for A3F binding.
- Mutating the A3G-binding region enhanced Vif's suppression of A3F.
- Vif binding to a Vif-resistant A3G mutant (D128K-A3G) depended on the Y(40)RHHY(44) region, while neutralization required the D(14)RMR(17) region.
Conclusions:
- HIV-1 Vif utilizes distinct regions for independent interactions with A3G and A3F.
- Interfering with Vif-APOBEC3 interactions presents a promising therapeutic strategy for controlling HIV-1 replication.
Abstract:
Human cytidine deaminases APOBEC3G (A3G) and APOBEC3F (A3F) inhibit replication of Vif-deficient human immunodeficiency virus type 1 (HIV-1). HIV-1 Vif overcomes these host restriction factors by binding to them and inducing their proteasomal degradation. The Vif-A3G and Vif-A3F interactions are attractive targets for antiviral drug development because inhibiting the interactions could allow the host defense mechanism to control HIV-1 replication. It was recently reported that the Vif amino acids D(14)RMR(17) are important for functional interaction and degradation of the previously identified Vif-resistant mutant of A3G (D128K-A3G). However, the Vif determinants important for functional interaction with A3G and A3F have not been fully characterized. To identify these determinants, we performed an extensive mutational analysis of HIV-1 Vif. Our analysis revealed two distinct Vif determinants, amino acids Y(40)RHHY(44) and D(14)RMR(17), which are essential for binding to A3G and A3F, respectively. Interestingly, mutation of the A3G-binding region increased Vif's ability to suppress A3F. Vif binding to D128K-A3G was also dependent on the Y(40)RHHY(44) region but not the D(14)RMR(17) region. Consistent with previous observations, subsequent neutralization of the D128K-A3G antiviral activity required substitution of Vif determinant D(14)RMR(17) with SEMQ, similar to the SERQ amino acids in simian immunodeficiency virus SIV(AGM) Vif, which is capable of neutralizing D128K-A3G. These studies are the first to clearly identify two distinct regions of Vif that are critical for independent interactions with A3G and A3F. Pharmacological interference with the Vif-A3G or Vif-A3F interactions could result in potent inhibition of HIV-1 replication by the APOBEC3 proteins.
More Related Videos
13:07Determining 3'-Termini and Sequences of Nascent Single-Stranded Viral DNA Molecules during HIV-1 Reverse Transcription in Infected Cells
Published on: January 30, 2019
07:10Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Leaky Scanning